| Nov 13 |
Industry Analysts Just Made A Notable Upgrade To Their Repare Therapeutics Inc. (NASDAQ:RPTX) Revenue Forecasts
|
| Nov 12 |
Repare Therapeutics collaborates with U.S. National Cancer Institute
|
| Nov 12 |
Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib
|
| Nov 7 |
Repare Therapeutics GAAP EPS of -$0.81
|
| Nov 7 |
Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results
|
| Oct 24 |
Repare Therapeutics’ individualised anaemia management trial shows promise
|
| Oct 23 |
Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial
|
| Oct 15 |
RPTX Stock Up as Dosing Begins in Solid Tumor Study for Combo Drug
|
| Oct 14 |
Repare Therapeutics doses first subject in Phase I solid tumour trial
|
| Oct 14 |
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor
|
